Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL37664 | 0.87 | HTR2A (0.62) | IDO1RAB9AAKR1C3HTR2AHTT | |
| SCHEMBL37665 | 0.85 | AKR1C3 (0.62) | IDO1RAB9AAKR1C3HTR2AHTT | |
| Hydrochloric Acid SCHEMBL11843534 | 0.84 | IDO1 (0.61) | IDO1RAB9AAKR1C3HTR2AHTT | |
| SCHEMBL11182492 | 0.84 | IDO1 (0.58) | IDO1RAB9AAKR1C3HTR2AHTT | |
| SCHEMBL6481479 | 0.84 | IDO1 (0.58) | IDO1RAB9AAKR1C3HTR2AHTT | |
| SCHEMBL11099610 | 0.84 | IDO1 (0.58) | IDO1RAB9AAKR1C3HTR2AHTT | |
| SCHEMBL1555636 | 0.84 | ALDH1A1 (0.59) | IDO1RAB9AAKR1C3HTR2AHTT | |
| SCHEMBL1013 | 0.84 | IDO1 (0.62) | IDO1RAB9AAKR1C3HTR2AHTT | |
| SCHEMBL17128295 | 0.84 | IDO1 (0.58) | IDO1RAB9AAKR1C3HTR2AHTT | |
| SCHEMBL4725847 | 0.84 | HTR2A (0.59) | IDO1RAB9AAKR1C3HTR2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5480987-A | 2-substituted alkyl-3-carboxy carbapenems as antibiotics and a method of producing them | AMERICAN CYANAMID COMPANY (US) | 1996-01-02 | — | — | US | claimed |
| US-5369102-A | B-lactamase inhibitors | AMERICAN CYANAMID COMPANY (US) | 1994-11-29 | — | — | US | claimed |
| EP-0478874-A2 | Novel 2-substituted alkyl-3-carboxy carbapenems as antibiotics and a method of producing them | AMERICAN CYANAMID COMPANY (US) | 1992-04-08 | — | — | EP | claimed |
| US-5068232-A | Bactericides | AMERICAN CYANAMID COMPANY (US) | 1991-11-26 | — | — | US | claimed |
| US-4639441-A | ANTIBACTERIAL PENICILLINS | SANKYO COMPANY LIMITED (JP) | 1987-01-27 | — | — | US | claimed |
| EP-0024832-A1 | Beta-lactam antibiotics, their preparation, pharmaceutical compositions containing them and their preparation | BEECHAM GROUP PLC (GB) | 1981-03-11 | — | — | EP | claimed |
| US-20130177963-A1 | ASYMMETRIC HYDROLASE AND GENE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-07-11 | — | — | US | disclosed |
| EP-2607480-A1 | Asymmetric hydrolase and gene thereof | Sumitomo Chemical Company, Limited (JP) | 2013-06-26 | — | — | EP | disclosed |
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| US-6867297-B1 | Process for synthesizing 4-substituted azetidinone derivatives | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-03-15 | — | — | US | disclosed |
| US-20050004092-A1 | Penem derivatives and antimicrobial agent containing the same | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-0757051-B1 | PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2003-10-29 | — | — | EP | disclosed |
| US-4331676-A | 2-PENEM COMPOUNDS UNSUBSTITUTED IN THE 6 POSITION | CIBA-GEIGY CORPORATION (US) | 1982-05-25 | — | — | US | disclosed |
| EP-0050927-A1 | The preparation of beta-lactam antibiotics | BEECHAM GROUP PLC (GB) | 1982-05-05 | — | — | EP | disclosed |
| US-4288364-A | REACTING A 3-/2-HYDROXYIMINOACETYLAMINO/-2-OXOAZETIDINE WITH AN ORGANIC CARBONATE OR ACYL HALIDE | CIBA-GEIGY CORPORATION (US) | 1981-09-08 | — | — | US | disclosed |
| EP-0024832-A1 | Beta-lactam antibiotics, their preparation, pharmaceutical compositions containing them and their preparation | BEECHAM GROUP PLC (GB) | 1981-03-11 | — | — | EP | disclosed |
| US-4248868-A | FOR TREATING SYSTEMIC INFECTIONS BY GRAMPOSITIVE AND GRAM NEGATIVE BACTERIA | CIBA-GEIGY CORPORATION (US) | 1981-02-03 | — | — | US | disclosed |
| US-4112110-A | Oxygenated azatetracyclic compounds | CIBA-GEIGY CORPORATION (US) | 1978-09-05 | — | — | US | disclosed |
| US-4070477-A | PENICILLINS | CIBA-GEIGY CORPORATION (US) | 1978-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | IDO1 3354/4885RAB9A 362/4885AKR1C3 1703/4885 |
| US-20050004092-A1 | Penem derivatives and antimicrobial agent containing the same | MRPL21, MRPS2, MRPS28 | IDO1 2202/4885RAB9A 2939/4885AKR1C3 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.